CLEVELAND, July 24, 2013 /CNW/ - ChanTest proudly announces that CEO, President and Founder, Arthur "Buzz" Brown, M.D., Ph.D. has been named the recipient of the prestigious Distinguished Service Award by the Safety Pharmacology Society (SPS). The following statement was issued by the SPS, "The award is in recognition of Dr. Brown's significant scientific contributions to many areas of Safety Pharmacology, most notably contributions to ion channels and their relationship to human disease."
The SPS will officially present the award at the 13th SPS Annual Meeting in Rotterdam, The Netherlands. As part of the ceremony, Dr. Brown will present a talk entitled, "Predicting Cardiac Safety: From Molecules to Man" on Thursday, September 19, 2013 from 11:30–12:00 at the Congress Centre de Doelen in Rotterdam.
Dr. Brown's establishment of ChanTest in 1998 allowed pharma and biotech companies to outsource important and unique safety pharmacology studies that have proven difficult and costly to implement "in-house". To this date, Dr. Brown's lab team at ChanTest continues to provide cutting edge assays that serve the Safety Pharmacology industry.
Dr. Brown collaborates with the US Federal Drug Administration (FDA) on cardiac safety issues and he holds nine patents on ion channel pharmacology, therapeutics and devices.
"I am honored to receive this award," said Dr. Brown. "The Safety Pharmacology Society has played a key role in the making of better and safer medicines by the pharmaceutical industry."
For more details about Dr. Brown's career, click here.
About ChanTest – The Ion Channel Expert
ChanTest's mission is to serve the drug discovery and development needs of customers worldwide with high-value solutions for ion channel and GPCR biology. Since its inception in 1998, the company has tested compounds for more than 300 global pharmaceutical and biotechnology companies and partners with them to speed the drug development process for the release of better, safer drugs. ChanTest offers integrated ion channel and GPCR services (GLP and non-GLP) and reagents; the company's library of validated ion channel cell lines and pre-clinical cardiac risk assessment service portfolio are the most comprehensive commercially available today. Because of ChanTest's seminal role in the nonclinical cardiac safety field, along with the company's uncompromising commitment to quality, ChanTest has been named the "most trusted and most used fee-for-service provider" for ion channel screening in independent surveys since 2006. ChanTest is based in Cleveland, Ohio. For more information, e-mail [email protected].
SOURCE: ChanTest Corporation
For further information:
Chris Mathes, Ph.D., Chief Commercial Officer, ChanTest Corporation, 216-584-0522, [email protected]
PRN Photo Desk, [email protected]